JP2016519680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519680A5 JP2016519680A5 JP2016505887A JP2016505887A JP2016519680A5 JP 2016519680 A5 JP2016519680 A5 JP 2016519680A5 JP 2016505887 A JP2016505887 A JP 2016505887A JP 2016505887 A JP2016505887 A JP 2016505887A JP 2016519680 A5 JP2016519680 A5 JP 2016519680A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 230000000155 isotopic effect Effects 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- -1 4-((4- (3- (5- (tert-butyl) -2-methoxy-3- (methylsulfonamido) phenyl) ureido) naphthalen-1-yl) oxy) pyrimidin-2-yl Chemical group 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 201000007407 panuveitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1305945.6 | 2013-04-02 | ||
| GB201305945A GB201305945D0 (en) | 2013-04-02 | 2013-04-02 | New compounds |
| GBGB1322678.2A GB201322678D0 (en) | 2013-12-20 | 2013-12-20 | New compounds |
| GB1322678.2 | 2013-12-20 | ||
| GB201402647A GB201402647D0 (en) | 2014-02-14 | 2014-02-14 | New compounds |
| GB1402647.0 | 2014-02-14 | ||
| PCT/GB2014/051018 WO2014162122A1 (en) | 2013-04-02 | 2014-04-01 | Kinase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519680A JP2016519680A (ja) | 2016-07-07 |
| JP2016519680A5 true JP2016519680A5 (enExample) | 2017-04-27 |
| JP6464384B2 JP6464384B2 (ja) | 2019-02-06 |
Family
ID=50434228
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016505888A Expired - Fee Related JP6495238B2 (ja) | 2013-04-02 | 2014-04-01 | キナーゼ阻害剤として有用な尿素誘導体 |
| JP2016505887A Expired - Fee Related JP6464384B2 (ja) | 2013-04-02 | 2014-04-01 | キナーゼ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016505888A Expired - Fee Related JP6495238B2 (ja) | 2013-04-02 | 2014-04-01 | キナーゼ阻害剤として有用な尿素誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8927563B2 (enExample) |
| EP (2) | EP2981535B8 (enExample) |
| JP (2) | JP6495238B2 (enExample) |
| KR (3) | KR102283883B1 (enExample) |
| CN (2) | CN105408315B (enExample) |
| AU (2) | AU2014246866B2 (enExample) |
| BR (2) | BR112015024678B1 (enExample) |
| CA (1) | CA2907663A1 (enExample) |
| DK (2) | DK2981535T3 (enExample) |
| EA (2) | EA030483B1 (enExample) |
| ES (2) | ES2904277T3 (enExample) |
| MX (2) | MX363949B (enExample) |
| TW (1) | TWI641592B (enExample) |
| WO (2) | WO2014162126A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ586418A (en) | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| JP5760010B2 (ja) | 2010-02-01 | 2015-08-05 | キャンサー・リサーチ・テクノロジー・リミテッド | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 |
| KR101995274B1 (ko) | 2011-10-03 | 2019-07-02 | 레스피버트 리미티드 | P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| AU2014246866B2 (en) | 2013-04-02 | 2018-05-10 | Oxular Acquisitions Limited | Kinase inhibitor |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2934199A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| PT3357919T (pt) | 2014-02-14 | 2020-02-20 | Respivert Ltd | Compostos heterocíclicos aromáticos como compostos antiinflamatórios |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| AR107165A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
| EA201892213A1 (ru) | 2016-04-06 | 2019-05-31 | Топайверт Фарма Лимитед | Ингибиторы киназ |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| CN110878055B (zh) * | 2018-09-06 | 2021-02-05 | 中国科学院化学研究所 | 一种制备羰基杂环类化合物的方法 |
| IL283755B2 (en) | 2018-12-07 | 2026-04-01 | Univ Maryland | N-(Phenyl-4-methylamino)-5-naphthalene-1-sulfonamide compounds and pharmaceutical preparations containing them |
| WO2022204046A1 (en) * | 2021-03-23 | 2022-09-29 | Gen1E Lifesciences Inc. | Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69826695T2 (de) | 1997-05-23 | 2006-02-02 | Bayer Pharmaceuticals Corp., West Haven | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen |
| EP1028953A1 (en) | 1997-11-03 | 2000-08-23 | Boehringer Ingelheim Pharmaceuticals Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| ATE278674T1 (de) | 1999-03-12 | 2004-10-15 | Boehringer Ingelheim Pharma | Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel |
| CA2374737C (en) | 1999-07-09 | 2008-02-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
| EP1232150B1 (en) | 1999-11-16 | 2007-10-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Urea derivatives as anti-inflammatory agents |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| WO2002083628A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused compounds |
| WO2002083642A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| JP2004530690A (ja) | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
| EP1395561A1 (en) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| WO2003005999A2 (en) | 2001-07-11 | 2003-01-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| US20040023961A1 (en) | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| EP1480973B1 (en) | 2002-02-25 | 2008-02-13 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| EP1549621A1 (en) | 2002-08-08 | 2005-07-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| WO2004113352A1 (en) | 2003-06-19 | 2004-12-29 | Amedis Pharmaceuticals Ltd. | Silylated heterocyclylurea derivatives as cytokine-inhibitors |
| WO2005005396A1 (en) | 2003-06-30 | 2005-01-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Process of making di-aryl urea compounds |
| CA2536293A1 (en) | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating copd and pulmonary hypertension |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| WO2005044825A1 (en) | 2003-10-21 | 2005-05-19 | Amedis Pharmaceuticals Ltd. | Silicon compounds and their use |
| PE20051046A1 (es) | 2003-11-28 | 2006-01-11 | Novartis Ag | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| TW200740820A (en) | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| PE20070795A1 (es) | 2005-10-28 | 2007-08-24 | Lilly Co Eli | Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| JP2012504591A (ja) | 2008-10-02 | 2012-02-23 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| MX2011006219A (es) | 2008-12-11 | 2011-06-28 | Respivert Ltd | Inhibidores de la proteina cinasa activada por el mitogeno p38. |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| ES2575084T3 (es) * | 2009-06-10 | 2016-06-24 | Chugai Seiyaku Kabushiki Kaisha | Compuesto tetracíclico |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| JP5708637B2 (ja) | 2010-03-15 | 2015-04-30 | 宇部興産株式会社 | アミド化合物の製造方法 |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
| JP5787976B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア |
| GB201009731D0 (en) * | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| WO2011158044A2 (en) | 2010-06-17 | 2011-12-22 | Respivert Limited | Respiratory formulations and compounds for use therein |
| GB201010196D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| WO2012044090A2 (ko) * | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| KR101995274B1 (ko) * | 2011-10-03 | 2019-07-02 | 레스피버트 리미티드 | P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아 |
| UA115320C2 (uk) | 2011-12-09 | 2017-10-25 | К'Єзі Фармачеутічі С.П.А. | Інгібітори кінази |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| AU2014246866B2 (en) * | 2013-04-02 | 2018-05-10 | Oxular Acquisitions Limited | Kinase inhibitor |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| CA2934199A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| PT3357919T (pt) | 2014-02-14 | 2020-02-20 | Respivert Ltd | Compostos heterocíclicos aromáticos como compostos antiinflamatórios |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| EA201892213A1 (ru) * | 2016-04-06 | 2019-05-31 | Топайверт Фарма Лимитед | Ингибиторы киназ |
-
2014
- 2014-04-01 AU AU2014246866A patent/AU2014246866B2/en not_active Ceased
- 2014-04-01 WO PCT/GB2014/051022 patent/WO2014162126A1/en not_active Ceased
- 2014-04-01 TW TW103112073A patent/TWI641592B/zh not_active IP Right Cessation
- 2014-04-01 EA EA201591906A patent/EA030483B1/ru not_active IP Right Cessation
- 2014-04-01 EP EP14716378.6A patent/EP2981535B8/en active Active
- 2014-04-01 DK DK14716378.6T patent/DK2981535T3/da active
- 2014-04-01 AU AU2014246870A patent/AU2014246870C1/en not_active Ceased
- 2014-04-01 US US14/242,531 patent/US8927563B2/en active Active
- 2014-04-01 US US14/242,741 patent/US9481648B2/en not_active Expired - Fee Related
- 2014-04-01 JP JP2016505888A patent/JP6495238B2/ja not_active Expired - Fee Related
- 2014-04-01 CN CN201480031577.7A patent/CN105408315B/zh not_active Expired - Fee Related
- 2014-04-01 ES ES14715106T patent/ES2904277T3/es active Active
- 2014-04-01 EA EA201591907A patent/EA027782B1/ru not_active IP Right Cessation
- 2014-04-01 BR BR112015024678-8A patent/BR112015024678B1/pt not_active IP Right Cessation
- 2014-04-01 KR KR1020157031292A patent/KR102283883B1/ko not_active Expired - Fee Related
- 2014-04-01 JP JP2016505887A patent/JP6464384B2/ja not_active Expired - Fee Related
- 2014-04-01 BR BR112015024671A patent/BR112015024671A2/pt active Search and Examination
- 2014-04-01 CA CA2907663A patent/CA2907663A1/en not_active Abandoned
- 2014-04-01 DK DK14715106.2T patent/DK2981526T3/da active
- 2014-04-01 MX MX2015013944A patent/MX363949B/es active IP Right Grant
- 2014-04-01 CN CN201480031484.4A patent/CN105246884B/zh not_active Expired - Fee Related
- 2014-04-01 WO PCT/GB2014/051018 patent/WO2014162122A1/en not_active Ceased
- 2014-04-01 MX MX2015013945A patent/MX363950B/es active IP Right Grant
- 2014-04-01 ES ES14716378T patent/ES2856902T3/es active Active
- 2014-04-01 EP EP14715106.2A patent/EP2981526B1/en active Active
- 2014-04-01 KR KR1020157031287A patent/KR102283876B1/ko not_active Expired - Fee Related
- 2014-04-01 KR KR1020217023664A patent/KR102340654B1/ko not_active Expired - Fee Related
-
2015
- 2015-02-19 US US14/626,548 patent/US20150166483A1/en not_active Abandoned
-
2016
- 2016-09-09 US US15/261,174 patent/US9790174B2/en not_active Expired - Fee Related
-
2017
- 2017-10-05 US US15/726,241 patent/US10435361B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519680A5 (enExample) | ||
| JP2017533895A5 (enExample) | ||
| JP2017505784A5 (enExample) | ||
| JP6608918B2 (ja) | Ｐ３８キナーゼ阻害剤としてのジアリール尿素誘導体 | |
| CN105408315B (zh) | 激酶抑制剂 | |
| JP2016515606A5 (enExample) | ||
| JP2015514794A5 (enExample) | ||
| JP2017535525A5 (enExample) | ||
| JP2014525426A5 (enExample) | ||
| JP2017502033A (ja) | キナーゼインヒビターとして有用な尿素誘導体 | |
| CA2932551A1 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP2017503835A5 (enExample) | ||
| CN105189453A (zh) | 氨磺酰基-芳基酰胺及其作为用于乙型肝炎治疗的药物的用途 | |
| JP2017502033A5 (enExample) | ||
| TW201116276A (en) | Glycine compounds | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| JP2019514861A5 (enExample) | ||
| ES2885573T3 (es) | Nuevos compuestos de tetrazol y su uso en el tratamiento de la tuberculosis | |
| CN103097365B (zh) | 作为鞘氨醇-1-磷酸(s1p)受体上的配体的5-(联苯-4-基)-3-苯基-1,2,4-噁二唑基衍生物 | |
| JP2013530182A (ja) | 新規なチオウレア又はウレア誘導体、その製造方法、及びそれを有効成分として含有するエイズ（ａｉｄｓ）予防又は治療用薬学組成物 | |
| IL296182A (en) | Inhibitors of human immunodeficiency virus replication | |
| JP2010514733A5 (enExample) | ||
| CN102574823B (zh) | 酰胺衍生物 | |
| CA2752804C (en) | Oxazole pyridine derivatives useful as s1p1 receptor agonists | |
| JP2025522539A (ja) | オキサジアゾール誘導体、その調製方法、及び炎症性疾患の治療におけるその使用 |